Skip to main content
Premium Trial:

Request an Annual Quote

DiaCarta Colorectal Cancer Test Gets CE-IVD Marking

NEW YORK (GenomeWeb) – Molecular diagnostics firm DiaCarta said yesterday it has received CE-IVD marking for its PCR-based kit to detect mutations associated with colorectal cancer.

The ColoScape test uses DiaCarta's QClamp XNA-based clamping technology and runs on commonly-used real-time PCR platforms in two-and-a-half hours. It requires as little as 20 ng of DNA from formalin-fixed, paraffin embedded tumor, stool, or plasma samples, and it detects 20 DNA mutation markers from four oncogenes, the firm said in a statement.

Study data generated by the company and its collaborators using the kit showed it identified greater than 95 percent of stage I-IV colorectal cancer cases, DiaCarta said.

"CE-IVD approval for the ColoScape kit means we can offer clinicians the ability to screen for CRC mutations from patient samples with the highest level of performance that the clinical setting demands," CEO of DiaCarta, Aiguo Zhang, said. "Our goal is to expand the global reach of this best-in-class clinical product with additional regulatory filings planned later this year and into 2018"

Additionally, the Richmond, California-based firm announced it has launched a CE-marked assay for ALK fusions, the QFusion ALK Fusion Gene Detection kit, which can detect as few as 50 fusion templates in a single reaction.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.